company background image
KNTE

Kinnate Biopharma NasdaqGS:KNTE Stock Report

Last Price

US$12.70

Market Cap

US$560.6m

7D

5.2%

1Y

-45.0%

Updated

28 Sep, 2022

Data

Company Financials +
KNTE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

KNTE Stock Overview

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States.

Kinnate Biopharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kinnate Biopharma
Historical stock prices
Current Share PriceUS$12.70
52 Week HighUS$26.05
52 Week LowUS$7.18
Beta0
1 Month Change-6.96%
3 Month Change0.71%
1 Year Change-44.97%
3 Year Changen/a
5 Year Changen/a
Change since IPO-67.46%

Recent News & Updates

Sep 21

FDA grants fast track nod to Kinnate Biopharma's skin cancer inhibitor

Clinical-stage oncology company Kinnate Biopharma (NASDAQ:KNTE) on Wednesday said it had got a fast track designation from the U.S. FDA for its inhibitor KIN-2787 for the treatment of patients with melanoma, the most serious type of skin cancer. The exact indication for KIN-2787 is for the treatment of patients with BRAF Class II or III alteration-positive and/or NRAS mutation-positive stage IIb to IV malignant melanoma that is metastatic or unresectable. The FDA's Fast Track approval is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. KIN-2787 is being evaluated in an ongoing phase 1 clinical trial in patients with solid tumors harboring BRAF alterations or who have NRAS mutant melanoma, KNTE said in a statement. The fast track nod for KIN-2787 follows an earlier orphan drug designation granted by the FDA for the treatment of stage IIb-IV melanoma. KNTE stock +4.8% to $12.65 after hours.

Sep 15
Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Kinnate Biopharma (NASDAQ:KNTE) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Aug 11

Kinnate Biopharma GAAP EPS of -$0.62 beats by $0.03

Kinnate Biopharma press release (NASDAQ:KNTE): Q2 GAAP EPS of -$0.62 beats by $0.03. As of June 30, 2022, the total of cash and cash equivalents and investments was $279.6 million, exclusive of Kinnjiu’s cash.

Shareholder Returns

KNTEUS BiotechsUS Market
7D5.2%2.9%-2.0%
1Y-45.0%-24.2%-20.3%

Return vs Industry: KNTE underperformed the US Biotechs industry which returned -27.4% over the past year.

Return vs Market: KNTE underperformed the US Market which returned -22.1% over the past year.

Price Volatility

Is KNTE's price volatile compared to industry and market?
KNTE volatility
KNTE Average Weekly Movement12.6%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: KNTE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: KNTE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201882Nima Farzanhttps://www.kinnate.com

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Kinnate Biopharma Fundamentals Summary

How do Kinnate Biopharma's earnings and revenue compare to its market cap?
KNTE fundamental statistics
Market CapUS$560.65m
Earnings (TTM)-US$104.83m
Revenue (TTM)n/a

0.0x

P/S Ratio

-5.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KNTE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$104.83m
Earnings-US$104.83m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.37
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did KNTE perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is KNTE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KNTE?

Other financial metrics that can be useful for relative valuation.

KNTE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-3.2x
PEG Ration/a

Price to Book Ratio vs Peers

How does KNTE's PB Ratio compare to its peers?

KNTE PB Ratio vs Peers
The above table shows the PB ratio for KNTE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2x
STOK Stoke Therapeutics
2.4x-5.2%US$528.2m
TSVT 2seventy bio
1.5x25.5%US$577.2m
JANX Janux Therapeutics
1.6x-14.5%US$564.4m
RPTX Repare Therapeutics
2.3x-16.1%US$517.5m
KNTE Kinnate Biopharma
2x-5.1%US$560.6m

Price-To-Book vs Peers: KNTE is expensive based on its Price-To-Book Ratio (2x) compared to the peer average (2x).


Price to Earnings Ratio vs Industry

How does KNTE's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: KNTE is expensive based on its Price-To-Book Ratio (2x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is KNTE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KNTE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate KNTE's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of KNTE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate KNTE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate KNTE's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Kinnate Biopharma forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-5.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: KNTE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KNTE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KNTE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KNTE is forecast to have no revenue next year.

High Growth Revenue: KNTE is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if KNTE's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Kinnate Biopharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-56.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: KNTE is currently unprofitable.

Growing Profit Margin: KNTE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: KNTE is unprofitable, and losses have increased over the past 5 years at a rate of 56.5% per year.

Accelerating Growth: Unable to compare KNTE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KNTE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: KNTE has a negative Return on Equity (-33.96%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Kinnate Biopharma's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: KNTE's short term assets ($267.1M) exceed its short term liabilities ($11.5M).

Long Term Liabilities: KNTE's short term assets ($267.1M) exceed its long term liabilities ($3.7M).


Debt to Equity History and Analysis

Debt Level: KNTE is debt free.

Reducing Debt: KNTE has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KNTE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KNTE has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 54.6% each year.


Discover healthy companies

Dividend

What is Kinnate Biopharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Kinnate Biopharma Dividend Yield vs Market
How does Kinnate Biopharma dividend yield compare to the market?
SegmentDividend Yield
Company (Kinnate Biopharma)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.7%
Analyst forecast in 3 Years (Kinnate Biopharma)0%

Notable Dividend: Unable to evaluate KNTE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate KNTE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if KNTE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if KNTE's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as KNTE has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Nima Farzan (46 yo)

2.5yrs

Tenure

US$7,884,041

Compensation

Mr. Nima Farzan, M.B.A., serves as President and Chief Executive Officer at Kinnate Biopharma Inc. and as a Member of Board of Directors since March 2020. Mr. Farzan had been the Chief Executive Officer at...


CEO Compensation Analysis

Nima Farzan's Compensation vs Kinnate Biopharma Earnings
How has Nima Farzan's remuneration changed compared to Kinnate Biopharma's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-US$105m

Mar 31 2022n/an/a

-US$99m

Dec 31 2021US$8mUS$558k

-US$90m

Sep 30 2021n/an/a

-US$77m

Jun 30 2021n/an/a

-US$63m

Mar 31 2021n/an/a

-US$49m

Dec 31 2020US$5mUS$359k

-US$36m

Compensation vs Market: Nima's total compensation ($USD7.88M) is above average for companies of similar size in the US market ($USD2.92M).

Compensation vs Earnings: Nima's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: KNTE's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: KNTE's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

NasdaqGS:KNTE Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
14 Mar 22BuyUS$338,850Richard WilliamsIndividual40,000US$8.64
15 Feb 22BuyUS$1,989,446OrbiMed Advisors LLCCompany195,700US$10.22

Ownership Breakdown

What is the ownership structure of KNTE?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders3,441,1697.4%
Institutions18,324,55339.3%
VC/PE Firms24,901,76053.4%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 100.75% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
24.55%
Foresite Capital Management, LLC
10,838,311$137.6m0%21.97%
9.66%
RA Capital Management, L.P.
4,264,144$54.2m0%1.07%
9.16%
OrbiMed Advisors LLC
4,043,629$51.4m0%0.83%
6.81%
Nextech Invest Ltd.
3,008,243$38.2m0%11.84%
6.22%
Vida Ventures Advisors, LLC
2,747,433$34.9m0%18.42%
5.21%
BlackRock, Inc.
2,299,544$29.2m11.89%no data
4.97%
FMR LLC
2,193,316$27.9m51.86%no data
4.19%
Tavistock Life Sciences
1,847,559$23.5m0%1.12%
4.12%
Viking Global Investors LP
1,820,462$23.1m0%0.1%
3.79%
Lynx1 Capital Management LP
1,674,677$21.3m141.83%18.01%
3.66%
Stephen Kaldor
1,615,826$20.5m0%no data
3.66%
Eric Murphy
1,615,826$20.5m0%no data
2.55%
Citadel Advisors LLC
1,127,389$14.3m-0.5%0.02%
2.26%
The Vanguard Group, Inc.
996,077$12.7m-31.57%no data
1.85%
Novo Holdings A/S
815,707$10.4m30.67%0.01%
1.4%
Rock Springs Capital Management LP
618,384$7.9m79.69%0.2%
1.13%
Harvard Management Company, Inc.
498,001$6.3m0%0.73%
1.02%
State Street Global Advisors, Inc.
452,278$5.7m6.88%no data
0.93%
Geode Capital Management, LLC
410,484$5.2m12.43%no data
0.72%
American Century Investment Management Inc
319,955$4.1m0.13%no data
0.7%
Federated Hermes, Inc.
307,800$3.9m0%0.01%
0.59%
Woodline Partners LP
260,276$3.3m0%0.05%
0.57%
Deerfield Management Company, L.P. Series C
250,000$3.2m-74.63%0.1%
0.51%
Northern Trust Global Investments
225,606$2.9m8.55%no data
0.51%
Dafna Capital Management, LLC
224,451$2.9m51.5%0.7%

Company Information

Kinnate Biopharma Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Kinnate Biopharma Inc.
  • Ticker: KNTE
  • Exchange: NasdaqGS
  • Founded: 2018
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$560.649m
  • Shares outstanding: 44.15m
  • Website: https://www.kinnate.com

Number of Employees


Location

  • Kinnate Biopharma Inc.
  • 103 Montgomery Street
  • Suite 150
  • San Francisco
  • California
  • 94129
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
6KBMUN (Boerse Muenchen)YesCommon StockDEEURDec 2020
KNTENasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDDec 2020

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/28 00:00
End of Day Share Price2022/09/28 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.